Jushi (OTCMKTS:JUSHF – Get Free Report) and IceCure Medical (NASDAQ:ICCM – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, institutional ownership, earnings, dividends, risk and analyst recommendations.
Institutional & Insider Ownership
21.7% of Jushi shares are held by institutional investors. Comparatively, 0.6% of IceCure Medical shares are held by institutional investors. 23.1% of Jushi shares are held by company insiders. Comparatively, 2.4% of IceCure Medical shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Profitability
This table compares Jushi and IceCure Medical’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Jushi | -24.44% | N/A | -15.46% |
| IceCure Medical | -427.67% | -174.26% | -112.58% |
Risk & Volatility
Earnings & Valuation
This table compares Jushi and IceCure Medical”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Jushi | $262.91 million | 0.32 | -$68.59 million | ($0.34) | -1.22 |
| IceCure Medical | $3.38 million | 2.29 | -$15.06 million | ($8.52) | -0.27 |
IceCure Medical has lower revenue, but higher earnings than Jushi. Jushi is trading at a lower price-to-earnings ratio than IceCure Medical, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a breakdown of recent recommendations and price targets for Jushi and IceCure Medical, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Jushi | 0 | 0 | 1 | 0 | 3.00 |
| IceCure Medical | 2 | 0 | 3 | 0 | 2.20 |
IceCure Medical has a consensus price target of $52.50, indicating a potential upside of 2,223.01%. Given IceCure Medical’s higher probable upside, analysts plainly believe IceCure Medical is more favorable than Jushi.
Summary
Jushi beats IceCure Medical on 8 of the 14 factors compared between the two stocks.
About Jushi
Jushi Holdings Inc., a vertically integrated cannabis company, engages in the cultivation, processing, retail, and distribution of cannabis for medical and adult-use markets. The company offers flower, extracts, concentrates, edibles, oil, pre-rolls, tinctures, capsules, softgels, cannabis-infused gummies and ultra-premium chocolate, and topicals products, as well as vaporization devices and cartridges under The Bank, The Lab, Nira+ Medicinals, Sèchè, Tasteology, and Hijinks brands. It is also involved in the bulk wholesale of refined cannabinoids and terpenes. In addition, the company operates medical cannabis dispensaries under the BEYOND/HELLO, Nature’s Remedy, and NuLeaf brands. It markets its products to local dispensaries and large multi-state operators. The company is headquartered in Boca Raton, Florida.
About IceCure Medical
IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. The company offers ProSense system, a single probe system for the treatment of tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology. It also develops XSense system, a single probe system; and MultiSense, a multi probe system for the treatment of multiple and larger tumors. The company was incorporated in 2006 and is headquartered in Caesarea, Israel.
Receive News & Ratings for Jushi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jushi and related companies with MarketBeat.com's FREE daily email newsletter.
